FDA approves medicine for treatment of deep vein thrombosis

Share this article:
FDA approves medicine for treatment of deep vein thrombosis
FDA approves medicine for treatment of deep vein thrombosis

The Food and Drug Administration has approved Janssen Pharmaceuticals, Inc.'s Xarelto (rivaroxaban ). Xarelto is intended for the treatment of deep vein thrombosis (DVT). If all or part of a DVT breaks off, it can travel to and lodge in the lungs, and can lead to potentially life-threatening consequences.


Share this article:

More in Products

Malnutrition remains issue

Identifying malnutrition in patients upon admission to a hospital is a low-cost way to improve patient outcomes and reduce readmissions, a new report says. Alleviating Hospital-Based Malnutrition: A Baseline Progress Report is an assessment of hospital-based malnutrition released in connection with the first anniversary of ...

Construction Specialties introduces wall and door protection

Construction Specialties introduces wall and door protection

Construction Specialties Inc. (C/S) has debuted a new line of wall and door protection, Acrovyn by Design and Acrovyn Doors by Design. The products embed high-resolution images and logos as ...

BioSensics launches ActivePERS fall detection

BioSensics launches ActivePERS fall detection

BioSensics has introduced ActivePERS, a personal emergency response and telemonitoring solution for seniors.